Home/Filings/4/0001192482-19-000421
4//SEC Filing

Friedman Ashley 4

Accession 0001192482-19-000421

CIK 0001561921other

Filed

Nov 12, 7:00 PM ET

Accepted

Nov 13, 8:48 PM ET

Size

20.4 KB

Accession

0001192482-19-000421

Insider Transaction Report

Form 4
Period: 2019-11-13
Transactions
  • Conversion

    Warrant (right to buy)

    2019-11-13+31,16831,168 total(indirect: By Partnership)
    Exercise: $28.65From: 2019-11-13Exp: 2027-01-18Common Stock (1,262 underlying)
  • Conversion

    Warrant (right to buy)

    2019-11-13+148,499148,499 total(indirect: By Partnership)
    Exercise: $28.65From: 2019-11-13Exp: 2027-01-18Common Stock (6,014 underlying)
  • Conversion

    Series B Preferred Stock

    2019-11-137,051,0090 total(indirect: By Partnership)
    Common Stock (285,580 underlying)
  • Conversion

    Common Stock

    2019-11-13+59,940106,052 total(indirect: By Partnership)
  • Conversion

    Common Stock

    2019-11-13+285,580505,281 total(indirect: By Partnership)
  • Conversion

    Warrant (right to buy)

    2019-11-1331,1680 total(indirect: By Partnership)
    Exercise: $1.16From: 2017-01-18Exp: 2027-01-18Series B Preferred Stock (31,168 underlying)
  • Conversion

    Series B Preferred Stock

    2019-11-131,479,9510 total(indirect: By Partnership)
    Common Stock (59,940 underlying)
  • Conversion

    Warrant (right to buy)

    2019-11-13148,4990 total(indirect: By Partnership)
    Exercise: $1.16From: 2017-01-18Exp: 2027-01-18Series B Preferred Stock (148,499 underlying)
Footnotes (5)
  • [F1]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
  • [F2]Reflects 46,112 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
  • [F3]Reflects 219,701 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
  • [F4]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
  • [F5]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.

Issuer

TELA Bio, Inc.

CIK 0001561921

Entity typeother

Related Parties

1
  • filerCIK 0001790193

Filing Metadata

Form type
4
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 8:48 PM ET
Size
20.4 KB